Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylamide SCHEMBL27915010 | 0.92 | CA1 (0.59) | CA1CA9ALDH1A1TSHRFGFR4 | |
| Butyrolactone SCHEMBL999308 | 0.86 | CA1 (0.54) | CA1CA9ALDH1A1TSHRLMNA | |
| Butyrolactone SCHEMBL28099382 | 0.83 | CA1 (0.61) | CA1CA9ALDH1A1TSHRLMNA | |
| Acrylic Acid SCHEMBL28002711 | 0.80 | CA1 (0.53) | CA1CA9ALDH1A1TSHRLMNA | |
| Acrylamide SCHEMBL29265380 | 0.79 | ALDH1A1 (0.48) | CA1CA9ALDH1A1TSHRFGFR4 | |
| Butyrolactone SCHEMBL9131954 | 0.79 | — | — | |
| Butyrolactone SCHEMBL3638548 | 0.79 | CA1 (0.61) | CA1CA9ALDH1A1TSHRLMNA | |
| Butyrolactone SCHEMBL9128999 | 0.79 | CA1 (0.61) | CA1CA9ALDH1A1TSHRLMNA | |
| Acrylic Acid SCHEMBL28693697 | 0.78 | CA1 (0.61) | CA1CA9ALDH1A1TSHRLMNA | |
| Acrylic Acid SCHEMBL30598695 | 0.78 | CA1 (0.61) | CA1CA9ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173210-B2 | Temperature-responsive degradable hydrogels | SONORAN BIOSCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200323987-A1 | TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS | SONORAN BIOSCIENCES, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| EP-3700589-A1 | TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS | Sonoran Biosciences, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323987-A1 | TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS | LCT, DLST, ALG1 | CA1 574/4885CA9 1123/4885ALDH1A1 1804/4885 |
| US-11173210-B2 | Temperature-responsive degradable hydrogels | LCT, DLST, ALG1 | CA1 574/4885CA9 1123/4885ALDH1A1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.